丹参川芎嗪注射液联合EC-T方案对乳腺癌术后患者近期疗效、免疫功能及生活质量的影响

张静; 刘银凤; 张轶雯; 高阳; 李燕莉

doi:10.14009/j.issn.1672-2124.2022.10.009

您当前的位置：

首页 >

文章列表页 >

丹参川芎嗪注射液联合EC-T方案对乳腺癌术后患者近期疗效、免疫功能及生活质量的影响

论著 | 更新时间：2023-04-16

- 丹参川芎嗪注射液联合EC-T方案对乳腺癌术后患者近期疗效、免疫功能及生活质量的影响
- Effects of Danshen Ligustrazine Injection Combined with EC-T Regimen on Short-Term Efficacy, Immune Function and Quality of Life in Patients with Breast Cancer After Surgery
- 中国医院用药评价与分析 2022年22卷第10期页码：1193-1195
- 作者机构：
  
  1. 秦皇岛市第一医院重症医学科
  2. 秦皇岛市第一医院乳腺外科
  3. 浙江省肿瘤医院乳腺外科
  4. 秦皇岛市第一医院普通外科
- 作者简介：
- 基金信息：
  
  2017年浙江省医药卫生科技计划项目(No.2017RC001)
- DOI：10.14009/j.issn.1672-2124.2022.10.009
  中图分类号： R737.9
- 纸质出版日期：2022，
扫描看全文
张静, 刘银凤, 张轶雯, 等. 丹参川芎嗪注射液联合EC-T方案对乳腺癌术后患者近期疗效、免疫功能及生活质量的影响[J]. 中国医院用药评价与分析, 2022,22(10):1193-1195.

ZHANG Jing, LIU Yinfeng, ZHANG Yiwen, et al. Effects of Danshen Ligustrazine Injection Combined with EC-T Regimen on Short-Term Efficacy, Immune Function and Quality of Life in Patients with Breast Cancer After Surgery[J]. 2022,22(10):1193-1195.
张静, 刘银凤, 张轶雯, 等. 丹参川芎嗪注射液联合EC-T方案对乳腺癌术后患者近期疗效、免疫功能及生活质量的影响[J]. 中国医院用药评价与分析, 2022,22(10):1193-1195. DOI： 10.14009/j.issn.1672-2124.2022.10.009.

ZHANG Jing, LIU Yinfeng, ZHANG Yiwen, et al. Effects of Danshen Ligustrazine Injection Combined with EC-T Regimen on Short-Term Efficacy, Immune Function and Quality of Life in Patients with Breast Cancer After Surgery[J]. 2022,22(10):1193-1195. DOI： 10.14009/j.issn.1672-2124.2022.10.009.

摘要

目的：探讨丹参川芎嗪注射液联合EC-T方案对乳腺癌术后患者近期疗效、免疫功能及生活质量的影响。方法：通过随机数字表法将2019年3月至2021年3月秦皇岛市第一医院收治的80例乳腺癌术后患者分为对照组与研究组(每组40例)

对照组患者给予EC-T方案治疗，研究组患者在对照组的基础上加用丹参川芎嗪注射液治疗。比较两组患者中医症状评分、免疫功能(CD3~+、CD4~+、CD8~+、CD4~+/CD8~+和自然杀伤细胞)和卡诺夫斯凯计分(KPS)变化情况，记录两组患者的近期疗效和不良反应发生情况。结果：与对照组(80.00%

32/40)相比，研究组患者的总有效率(95.00%

38/40)更高，差异有统计学意义(χ~2=4.114

P=0.043)。治疗后，两组患者各项中医症状评分均明显降低，且研究组患者失眠、乏力疲惫、乳房胀痛、出汗和口干评分明显低于对照组，差异均有统计学意义(P<0.05)。治疗后，两组患者CD3~+、CD4~+及CD4~+/CD8~+水平明显升高，CD8~+水平明显降低；且与对照组相比，研究组患者治疗后的CD3~+、CD4~+及CD4~+/CD8~+水平明显更高，CD8~+水平明显更低，差异均有统计学意义(P<0.05)。治疗后，两组患者的KPS评分均明显升高，且研究组患者治疗后的KPS评分明显高于对照组，差异有统计学意义(P<0.05)。研究组患者心脏毒性、血小板减少、脱发、恶心呕吐和白细胞减少的发生率明显低于对照组，差异均有统计学意义(P<0.05)。结论：针对乳腺癌术后患者，采用丹参川芎嗪注射液联合EC-T方案治疗能取得理想的疗效，不但可缓解临床症状，还能改善免疫功能，减少不良反应，提高生活质量。

Abstract

OBJECTIVE: To probe into the effects of Danshen Ligustrazine injection combined with EC-T regimen on short-term efficacy

immune function and quality of life in patients with breast cancer after surgery. METHODS: A total of 80 breast cancer patients admitted into Qinhuangdao the First Hospital from Mar. 2019 to Mar. 2021 were extracted to be divided into the control group and the treatment group via the random number table method（with 40 cases in each group）. The study group was treated with EC-T regimen

while the treatment group was additionally given Danshen Ligustrazine injection based on the study group. Changes of traditional Chinese medicine symptom score

immune function（CD3

CD4

CD8

CD4

/CD8

and NK cells） and Kanofsky performance score（KPS） were compared between two groups

and the short-term efficacy and adverse drug reactions of two groups were recorded. RESULTS: Compared with the control group（80.00%

32/40）

the total effective rate of the treatment group（95.00%

38/40） was higher

and the difference was statistically significant（χ~2=4.114

P=0.043）. After treatment

the traditional Chinese medicine symptom score in two groups decreased significantly

and the scores of insomnia

fatigue

breast pain

sweating and dry mouth in the treatment group were significantly lower than those in the control group

the differences were statistically significant（P

0.05）. After treatment

the levels of CD3

CD4

and CD4

/CD8

in two groups increased significantly

while the levels of CD8

decreased significantly

and compared with the control group

the levels of CD3

CD4

and CD4

/CD8

in the treatment group after treatment were significantly higher

and the levels of CD8

were significantly lower

the differences were statistically significant（P

0.05）. After treatment

the KPS score of two groups increased significantly

and the KPS score of the treatment group was significantly higher than that of the control group

the difference was statistically significant（P

0.05）. The incidence of cardiotoxicity

thrombocytopenia

alopecia

nausea and vomiting and leukopenia in the treatment group were significantly lower than those in the control group

with statistically significant differences（P

0.05）. CONCLUSIONS: For patients with breast cancer after surgery

the treatment of Danshen Ligustrazine injection combined with EC-T regimen can achieve ideal clinical efficacy

which not only can relieve the clinical symptoms

but improve the immune function

reduce the adverse drug reactions

and improve the quality of life.

关键词

丹参川芎嗪注射液EC-T方案乳腺癌免疫功能生活质量

Keywords

Danshen Ligustrazine injectionEC-T regimenBreast cancerImmune functionQuality of life

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

参麦注射液对乳腺癌术后化疗患者心肌功能和免疫功能的影响

吉西他滨联合顺铂/洛铂髂内动脉化疗栓塞治疗肌层浸润性膀胱尿路上皮癌的疗效观察

纤维支气管镜肺泡灌洗联合阿奇霉素对支原体肺炎患儿免疫功能，血清MCP-4、MAPK和CysLTR1水平的影响

清热化痰汤联合桑白皮汤对痰热郁肺型慢性阻塞性肺疾病患者肺通气功能、免疫功能的影响

全身麻醉期间持续静脉输注右美托咪定联合羟考酮对乳腺癌患者炎症反应及免疫功能的影响